Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.06 -14.5%	$0.17	$0.05 ▼ $1.32	$18.26M	2.18	87.47 million shs	40.30 million shs
AUTL Autolus Therapeutics	$1.50 -4.5%	$2.22	$1.11 ▼ $5.00	$417.84M	1.9	2.84 million shs	2.14 million shs
CRGX CARGO Therapeutics	$4.47	$4.45	$3.00 ▼ $25.45	$216.17M	0.3	1.73 million shs	N/A
DNTH Dianthus Therapeutics	$23.57 -5.0%	$20.60	$13.36 ▼ $32.27	$798.59M	1.43	382,629 shs	345,906 shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+15.41%	+17.78%	-34.32%	-74.00%	-94.35%
AUTL Autolus Therapeutics	0.00%	-10.29%	-35.12%	-9.77%	-59.95%
CRGX CARGO Therapeutics	0.00%	0.00%	-0.45%	+5.42%	-73.66%
DNTH Dianthus Therapeutics	+2.35%	+4.90%	+15.99%	+42.42%	-12.61%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	1.7554 of 5 stars	3.0	3.0	2.1	1.7	0.0
AUTL Autolus Therapeutics	2.7186 of 5 stars	3.5	1.0	3.0	3.3	0.6
CRGX CARGO Therapeutics	2.0037 of 5 stars	2.9	0.0	2.0	1.7	1.3
DNTH Dianthus Therapeutics	1.1493 of 5 stars	3.5	0.0	1.9	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	2,194.85% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.12	508.00% Upside
CRGX CARGO Therapeutics	1.86	Reduce	$15.40	244.52% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$54.00	129.10% Upside

Current Analyst Ratings Breakdown

Latest ADAP, DNTH, AUTL, and CRGX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	DNTH Dianthus Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$34.00 ➝ $42.00
8/13/2025	AUTL Autolus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$6.00 ➝ $5.00
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/21/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
7/8/2025	CRGX CARGO Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$3.70 ➝ $5.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.09	N/A	N/A	($0.27) per share	-0.22
AUTL Autolus Therapeutics	$10.12M	39.45	N/A	N/A	$1.30 per share	1.15
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	$4.91 per share	N/A
DNTH Dianthus Therapeutics	$6.24M	121.59	N/A	N/A	$9.42 per share	2.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.65	N/A	N/A	N/A	-260.82%	-163.73%	-75.83%	11/12/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.84	N/A	N/A	N/A	N/A	-56.18%	-29.61%	11/11/2025 (Estimated)
CRGX CARGO Therapeutics	-$167.50M	-$4.64	N/A	N/A	N/A	N/A	-43.21%	-37.26%	11/11/2025 (Estimated)
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	11/6/2025 (Estimated)

Latest ADAP, DNTH, AUTL, and CRGX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.15	-$0.11	+$0.04	-$0.11	$11.04 million	$13.68 million
8/12/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.24	-$0.18	+$0.06	-$0.18	$12.92 million	$13.50 million
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
CRGX CARGO Therapeutics	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	1.52	1.29
AUTL Autolus Therapeutics	N/A	8.43	8.07
CRGX CARGO Therapeutics	N/A	12.37	12.37
DNTH Dianthus Therapeutics	N/A	13.12	13.12

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
AUTL Autolus Therapeutics	72.83%
CRGX CARGO Therapeutics	93.16%
DNTH Dianthus Therapeutics	47.53%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
AUTL Autolus Therapeutics	25.70%
CRGX CARGO Therapeutics	2.92%
DNTH Dianthus Therapeutics	8.15%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
CRGX CARGO Therapeutics	116	48.36 million	46.95 million	N/A
DNTH Dianthus Therapeutics	80	32.19 million	29.57 million	Optionable

ADAP, DNTH, AUTL, and CRGX Headlines

Recent News About These Companies

Wedbush Forecasts Reduced Earnings for Dianthus Therapeutics

August 26 at 2:51 AM | americanbankingnews.com

Wedbush Lowers Earnings Estimates for Dianthus Therapeutics

August 26 at 2:28 AM | marketbeat.com

Candriam S.C.A. Makes New Investment in Dianthus Therapeutics, Inc. $DNTH

August 25, 2025 | marketbeat.com

Wedbush Raises Dianthus Therapeutics (NASDAQ:DNTH) Price Target to $42.00

August 24, 2025 | americanbankingnews.com

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Up 6.7% - Here's What Happened

August 21, 2025 | marketbeat.com

Lifesci Capital Has Bearish Estimate for DNTH Q3 Earnings

August 17, 2025 | marketbeat.com

FY2025 EPS Estimates for DNTH Cut by Cantor Fitzgerald

August 15, 2025 | marketbeat.com

HC Wainwright Has Bearish Forecast for DNTH Q3 Earnings

August 14, 2025 | marketbeat.com

What is William Blair's Estimate for DNTH Q1 Earnings?

August 12, 2025 | marketbeat.com

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Recommendation of "Buy" from Analysts

August 10, 2025 | marketbeat.com

Dianthus (DNTH) Q2 Loss Widens 80%

August 8, 2025 | aol.comA

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

August 7, 2025 | globenewswire.com

Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline

August 7, 2025 | zacks.com

Dianthus Therapeutics (DNTH) Expected to Announce Earnings on Thursday

August 7, 2025 | marketbeat.com

Dianthus Therapeutics’ CAPTIVATE Study: A Potential Game-Changer for CIDP Treatment

July 28, 2025 | tipranks.com

Dianthus Therapeutics Inc News (DNTH) - Investing.com

July 11, 2025 | investing.com

William Blair Initiates Coverage of Dianthus Therapeutics (DNTH) with Outperform Recommendation

July 3, 2025 | msn.com

Dianthus Therapeutics stock rises after William Blair initiates coverage

July 2, 2025 | in.investing.com

Dianthus Therapeutics Shares Climb After Analyst Coverage Boost

July 2, 2025 | msn.com

DNTH - Dianthus Therapeutics Inc Price vs Fair Value - Morningstar

June 26, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ADAP, DNTH, AUTL, and CRGX Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.06 -0.01 (-14.51%)

Closing price 04:00 PM Eastern

Extended Trading

$0.06 +0.00 (+0.85%)

As of 08:00 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Autolus Therapeutics NASDAQ:AUTL

$1.50 -0.07 (-4.46%)

Closing price 04:00 PM Eastern

Extended Trading

$1.50 +0.00 (+0.33%)

As of 07:49 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

CARGO Therapeutics NASDAQ:CRGX

$4.47 0.00 (0.00%)

As of 08/19/2025

CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.

Dianthus Therapeutics NASDAQ:DNTH

$23.57 -1.24 (-5.00%)

Closing price 04:00 PM Eastern

Extended Trading

$23.61 +0.04 (+0.17%)

As of 07:57 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time